Newsroom | 18645 results

Sorted by: Latest
Genetics
-

Ossium Health to Present New Clinical Data from PRESERVE I Study at the 2026 Tandem Meetings

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings on February 4-7, 2026 in Salt Lake City....
-

Riassunto: Raggiunto l'endpoint primario della sopravvivenza globale nel trial pivotale di fase 3 ROSELLA con Relacorilant in pazienti con carcinoma ovarico resistente al platino di Corcept

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), un'azienda commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie endocrine, oncologiche, metaboliche e neurologiche attraverso la modulazione degli effetti dell'ormone cortisolo, oggi ha annunciato che ROSELLA, lo studio clinico pivotale di fase 3 dell'azienda su relacorilant più nab-paclitaxel nel trattamento di pazienti con carcinoma ovarico resistente al p...
-

Samenvatting: Primair eindpunt van algehele overleving voldaan in Corcepts cruciale Fase 3-studie ROSELLA van relacorilant bij patiënten met platina-resistente eierstokkanker

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), een bedrijf in commerciële fase dat zich inzet voor het ontdekken en ontwikkelen van geneesmiddelen om ernstige endocriene, oncologische, metabolische en neurologische stoornissen te behandelen door de effecten van het hormoon cortisol te moduleren, maakte vandaag bekend dat ROSELLA, de cruciale Fase 3-studie van relacorilant plus nab-paclitaxel van het bedrijf om patiënten met platina-resistente eierstokka...
-

Resumen: El crucial ensayo ROSELLA fase 3 de relacorilant de Corcept cumplió el criterio de evaluación principal de supervivencia general en pacientes con cáncer ovárico resistente al platino

REDWOOD CITY, California--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), una empresa de fase comercial dedicada al descubrimiento y el desarrollo de medicamentos para el tratamiento de trastornos endocrinos, oncológicos, metabólicos y neurológicos graves mediante la modulación de los efectos de la hormona cortisol, anunció hoy que ROSELLA, el crucial ensayo fase 3 de la empresa de relacorilant junto a nab-paclitaxel para el tratamiento de pacientes con cáncer ovárico resiste...
-

Critère principal de survie globale atteint dans l’essai pivot ROSELLA de phase 3 de Corcept évaluant le rélacorilant chez les patientes atteintes d’un cancer de l’ovaire résistant au platine

REDWOOD CITY, Californie--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ : CORT), une société de phase commerciale spécialisée dans la découverte et le développement de médicaments pour traiter les troubles endocrinologiques, oncologiques, métaboliques et neurologiques graves en modulant les effets de l’hormone cortisol, annonce aujourd’hui que ROSELLA, l’essai pivot de phase 3 de la société sur le rélacorilant plus nab-paclitaxel pour traiter les patientes atteintes d’un cancer de...
-

Primärer Endpunkt der Gesamtüberlebensrate in der zulassungsrelevanten Phase-3-Studie ROSELLA von Corcept mit Relacorilant bei Patientinnen mit platinresistentem Eierstockkrebs erreicht

REDWOOD CITY, Kalifornien--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), ein im kommerziellen Stadium tätiges Unternehmen, das Medikamente zur Behandlung schwerer endokrinologischer, onkologischer, metabolischer und neurologischer Erkrankungen durch Modulation der Wirkung des Hormons Cortisol erforscht und entwickelt, gab heute bekannt, dass ROSELLA, die zulassungsrelevante Phase-3-Studie des Unternehmens zu Relacorilant plus Nab-Paclitaxel zur Behandlung von Patientinnen m...
-

Legislation In Florida Seeks To Increase Access To Genetic Testing

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) for introducing legislation that would eliminate financial barriers for patients requiring clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing. Germline testing is a type of test that looks for inherited mutations that have been present...
-

Legislation In Mississippi Seeks To Increase Access To Genetic Testing

JACKSON, Miss.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Representative Samuel Creekmore, IV (R-New Albany) for introducing legislation that would eliminate financial barriers for patients requiring clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing. Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth. In...
-

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary...
-

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, is advancing both its scientific foundation for its D-Domain platform technology and commercial preparedness for anito-cel for the potential treatment of multiple myeloma with three presentations at the 2026 Tandem Meetings. One presentation reinforces anito-cel’s unique...